Figure 3.

Kaplan-Meier plots of OS by response in FKSI-19 total score at the 3-month landmark for each treatment group (threshold = 5): patients with intermediate- or poor-risk RCC (all randomized)^a. (A) Nivolumab + ipilimumab. (B) Sunitinib alone. ^aHR is relative to patients with a worsening or unobserved HRQoL response, with HR < 1 favoring patients with stable or improved HRQoL. HR is derived from a stratified Cox regression model with response as the only covariate and strata as the randomization factors. The P-value corresponds to the Cox regression model.